Sanofi (SNY) Reports Q3 EPS of EUR1.25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Sanofi - Q3 2015 Results
October 29, 2015 3:53 AM EDTPARIS, October 29, 2015 /PRNewswire/ --
Sanofi, a global and diversified healthcare leader, reports results for the third quarter of 2015. Jérôme Contamine, Chief Financial Officer of Sanofi, comments on the Group's Q3 results.
Watch video interview and read... More
Sanofi grew sales and business EPS(1) in Q3 2015
October 29, 2015 2:47 AM EDTPARIS, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Group sales(2) increased 3.4% (up 9.2% on a reported basis) to 9,591 million Diabetes sales decreased 6.6%, as a result of lower U.S. sales of Lantus® Genzyme sales (up 32.7%) showed strong momentum driven by Multiple Sclerosis products Vaccines sales were up 5.5% mainly driven by Emerging Markets(3) Animal Health delivered another strong performance (up 9.3%) driven by NexGard® Emerging Markets sales increased by 11.4% Steady financial performance taking into account higher investments in new products
Operating expenses were 3,816m, up 7.5% at CER Business net income grew 5.0% at CER (up 8.3% on a reported basis) to 2,096 million Business EPS increased 6.1%... More
